Document is current
Any future updates will be listed below
-
Authors
Boutin, Sébastien
Klein, Sabrina
Untergasser, Gerold
Loka, Tobias P.
Jakob, Suzan
Caf, Yasemin
Khatamzas, Elham
Knabl, Ludwig
Wrettos, Georg
Knobloch, Henri
Nurjadi, Dennis
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
- License Information
-
More Information
Article History
Received: 8 May 2025
Accepted: 7 October 2025
First Online: 11 November 2025
Declarations
:
: Tobias P. Loka and Henri Knobloch are co-founders and shareholders of Seqstant GmbH, a company that offers live sequencing analysis methods for clinical applications, including the software used in this study. Tobias P. Loka and Henri Knobloch are further inventors of patent WO-2022243192-A1 that is held by Seqstant GmbH and covers the method for parallel real-time sequence analysis of Illumina sequencing data. Dennis Nurjadi received speaker’s honorarium from Cepheid and Shionogi outside the scope of this work. All other authors reported no conflicts of interest. Sabrina Klein received speaker`s honorarium and financial compensation for data extraction from Pfizer Pharma unrelated to this study.
: The local ethics committee approved the study protocol and waived informed consent (S-062/2022).
: Not applicable.
